A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited

Slides:



Advertisements
Similar presentations
MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
Advertisements

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
Clinical Conference 10/23/ y.o. with h/o HTN, presented to Palos ER with SSCP SH: remote tob FH: no early CAD All: NKDA Meds: lisinopril 5mg.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Types of Hemodynamic Support in the Cath Lab.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
IABP-SHOCK II Score Stratifies Patient Risk in CS after AMI
Improving Outcomes in Cardiogenic Shock
Nat. Rev. Cardiol. doi: /nrcardio
Fig. 1. Patient transferred to ICU with IABP inserted surgically through left axillary artery approached at deltoido-pectoralis groove (a). Correct position.
Treatment of acute renal failure
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.
Trends in Coronary Procedures per 1000 Medicare Beneficiaries
Current Dyslipidemia Management Guidelines Residual Risk.
Atrial Fibrillation and PCI
Acute Heart Failure.
Updates in Anticoagulation: What Did We Learn From ESC 2017?
Cardiogenic Shock.
The Clinical Enigma of Cardiogenic Shock
US Guidelines US Guidelines Low-risk Patients.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Does One Size Fit All in Obesity Management?
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
PAD Patients vs Post-ACS Patients:
A New Era for NOACs:.
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.
Examining CV Effects of Basal Insulin Therapy
Antithrombotics and PAD: A New Paradigm in Practice
Percutaneous Mechanical Circulatory Support Devices
What Has Been Tried and What Is True?
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.
Considerations for Percutaneous Coronary Intervention (PCI)
Efficacy and Safety of Edoxaban in Patients With AF and HF
CV Risk Doesn't End in the Cath Lab
AF and PCI in Practice.
CoreValve US Pivotal Trial High-Risk Arm Device and Access Routes.
TAVR and the Risk of Thrombosis
VTE in Cancer.
Remote Patient Management:
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
Using Heart Rate as a Biomarker in Clinical Practice.
CV Risk Doesn't End in the Cath Lab
ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.
Physiology Myocardial Oxygen Supply and Demanda,b.
Aspirin and Cardioprevention in 2018
Nat. Rev. Cardiol. doi: /nrcardio
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Juan J. Russo et al. JACC 2019;73:
Updates in Anticoagulation: Key Sessions at ESC 2017
PeaceHealth Southwest Hospital/Carson Tahoe Medical Center
Elevated Admission Plasma Glucose Following ACS
DECLARE-TIMI 58.
Treatment of acute renal failure
Ischemic Postconditioning
What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.
Intra-Aortic Balloon Pumps
IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.
Evaluating the Science of Cardiogenic Shock
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
My PAH Patient.
Expert Perspectives.
Kaplan-Meier estimates of all-cause mortality at 30 days.
Independent predictors of all-cause mortality at 30 days.
The Power of As-Treated Analyses
Presentation transcript:

A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited

Cardiogenic Shock

Intra-aortic Balloon Pumps in Patients With Cardiogenic Stroke

Cardiogenic Shock: One Size Does Not Fit All

Cardiogenic Shock: Clinical Presentation

IABP-Shock-II Trial

Patient Characteristics

Clinical Outcome: 12 Months

IABP-SHOCK II Trial: No Benefit/No Harm

Patients in IABP-SHOCK II Trial

IABP Prior to Revascularization

Clinical Implications

PRAMI: Complete Revascularization at the Time of Primary PCI

Cardiogenic Shock

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)